复发难治性弥漫性大B细胞淋巴瘤的管理
Management of relapsed-refractory diffuse large B cell lymphoma.
作者信息
Raut Lalit S, Chakrabarti Prantar P
机构信息
Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India.
出版信息
South Asian J Cancer. 2014 Jan;3(1):66-70. doi: 10.4103/2278-330X.126531.
Abstract
Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.
摘要
复发难治性弥漫性大B细胞淋巴瘤（RR DLBCL）约占DLBCL患者的三分之一，仍然是发病和死亡的主要原因。对血液肿瘤医生来说，治疗RR DLBCL仍然是一项挑战。挽救性大剂量化疗后进行自体干细胞移植是DLBCL化疗敏感复发的标准治疗方法。有多种挽救方案可供选择，但寻找最佳方案的工作仍在继续。在挽救方案中加入利妥昔单抗改善了RR DLBCL的治疗效果。本简短综述讨论了关于RR DLBCL治疗的几个相关问题。
相似文献
1
Management of relapsed-refractory diffuse large B cell lymphoma.复发难治性弥漫性大B细胞淋巴瘤的管理
South Asian J Cancer. 2014 Jan;3(1):66-70. doi: 10.4103/2278-330X.126531.
2
Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.利妥昔单抗时代弥漫性大B细胞淋巴瘤患者大剂量化疗及自体干细胞移植后的晚期复发
Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):145-151. doi: 10.1016/j.clml.2016.11.001. Epub 2016 Nov 23.
3
SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies.SOHO最新技术进展与后续问题 | 细胞疗法时代自体干细胞移植在复发/难治性弥漫性大B细胞淋巴瘤治疗中的当代作用
Clin Lymphoma Myeloma Leuk. 2025 Apr;25(4):219-225. doi: 10.1016/j.clml.2024.07.020. Epub 2024 Aug 3.
4
A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.一项 I/II 期临床试验，旨在评估挽救性治疗的安全性、可行性和疗效，该治疗方案由 mTOR 抑制剂替西罗莫司联合标准治疗方案利妥昔单抗和 DHAP（地塞米松、阿糖胞苷、顺铂）组成，用于治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者 - STORM 试验。
BMC Cancer. 2013 Jun 25;13:308. doi: 10.1186/1471-2407-13-308.
5
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.复发或难治性弥漫性大B细胞淋巴瘤的治疗选择。第1部分。当前的治疗方法。
Oncology (Williston Park). 2009 May;23(6):546-53.
6
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.复发/难治性弥漫性大B细胞淋巴瘤中用于个性化精准医学的新型药物靶点：综述
Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2.
7
Management of Relapsed Diffuse Large B-cell Lymphoma.复发性弥漫性大B细胞淋巴瘤的管理
Hematol Oncol Clin North Am. 2016 Dec;30(6):1195-1213. doi: 10.1016/j.hoc.2016.07.004.
8
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.自体造血干细胞移植后利妥昔单抗维持治疗复发 CD20(+)弥漫性大 B 细胞淋巴瘤患者：复发侵袭性淋巴瘤合作研究的最终分析。
J Clin Oncol. 2012 Dec 20;30(36):4462-9. doi: 10.1200/JCO.2012.41.9416. Epub 2012 Oct 22.
9
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.利妥昔单抗既往治疗对复发或难治性侵袭性B细胞淋巴瘤患者自体干细胞移植结局的影响：一项西班牙淋巴瘤/自体骨髓移植研究组的多中心回顾性研究
Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26.
10
High-dose rituximab in combination with autologous stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma.大剂量利妥昔单抗联合自体干细胞移植治疗复发或难治性弥漫性大B细胞淋巴瘤。
Med Clin (Barc). 2020 Sep 25;155(6):235-241. doi: 10.1016/j.medcli.2019.11.009. Epub 2020 Mar 12.
引用本文的文献
1
Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL.基于系统生物学的NF-κΒ和BCL2靶向作用克服了弥漫性大B细胞淋巴瘤中微环境介导的BH3模拟物耐药性。
Cell Death Dis. 2025 Aug 16;16(1):620. doi: 10.1038/s41419-025-07942-0.
2
High SRD5A3 expression is correlated with promotion of proliferation and inhibition of apoptosis in B-cell non-Hodgkin lymphoma and suggests a poor prognosis.SRD5A3高表达与B细胞非霍奇金淋巴瘤的增殖促进和凋亡抑制相关，并提示预后不良。
PLoS One. 2025 May 21;20(5):e0323965. doi: 10.1371/journal.pone.0323965. eCollection 2025.
3
Tumour Microenvironment: The General Principles of Pathogenesis and Implications in Diffuse Large B Cell Lymphoma.肿瘤微环境：弥漫性大 B 细胞淋巴瘤发病机制的一般原则及其影响。
Cells. 2024 Jun 18;13(12):1057. doi: 10.3390/cells13121057.
4
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.新发弥漫性大B细胞淋巴瘤（DLBCL）的流行病学及真实世界治疗情况：一项德国医保理赔数据分析
Oncol Ther. 2024 Jun;12(2):293-309. doi: 10.1007/s40487-024-00265-8. Epub 2024 Feb 20.
5
Ibrutinib Plus RCHOP versus RCHOP Only in Young Patients with Activated B-Cell-like Diffuse Large B-Cell Lymphoma (ABC-DLBCL): A Cost-Effectiveness Analysis.伊布替尼联合 RCHOP 与 RCHOP 单独治疗活化 B 细胞样弥漫性大 B 细胞淋巴瘤（ABC-DLBCL）年轻患者的成本效果分析。
Curr Oncol. 2023 Dec 15;30(12):10488-10500. doi: 10.3390/curroncol30120764.
6
The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review.西达本胺在 B 细胞非霍奇金淋巴瘤治疗中的作用：一项更新的系统评价。
Biomol Biomed. 2023 Sep 4;23(5):727-739. doi: 10.17305/bb.2023.8791.
7
Investigating In Situ Expression of c-MYC and Candidate Ubiquitin-Specific Proteases in DLBCL and Assessment for Peptidyl Disruptor Molecule against c-MYC-USP37 Complex.研究弥漫性大 B 细胞淋巴瘤中 c-MYC 和候选泛素特异性蛋白酶的原位表达情况，并评估针对 c-MYC-USP37 复合物的肽结构破坏分子。
Molecules. 2023 Mar 7;28(6):2441. doi: 10.3390/molecules28062441.
8
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.在美国，对于三线或三线以上复发或难治性大 B 细胞淋巴瘤患者，利妥昔单抗注射用偶联物与阿基仑赛注射液和西达基奥仑赛注射液相比的成本效果分析。
Adv Ther. 2023 May;40(5):2355-2374. doi: 10.1007/s12325-023-02444-x. Epub 2023 Mar 22.
9
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).复发/难治性 B 细胞淋巴瘤（包括弥漫性大 B 细胞淋巴瘤）中脾酪氨酸激酶/FMS 样酪氨酸激酶-3 抑制：米伐莫汀（TAK-659/CB-659）的更新数据。
Oncotarget. 2023 Jan 26;14:57-70. doi: 10.18632/oncotarget.28352.
10
Lesion-to-Liver SUVmax Ratio to Improve the Prognostic Value of the End of Treatment PET/CT in Diffuse Large B-Cell Lymphoma.病灶与肝脏SUVmax比值可提高弥漫性大B细胞淋巴瘤治疗结束时PET/CT的预后价值。
J Clin Med. 2022 Sep 21;11(19):5541. doi: 10.3390/jcm11195541.
本文引用的文献
1
Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.利妥昔单抗时代后弥漫性大 B 细胞淋巴瘤治疗的基于 interim PET/CT 的预后模型。
Ann Hematol. 2013 Apr;92(4):471-9. doi: 10.1007/s00277-012-1640-x. Epub 2012 Dec 13.
2
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation.一名复发性弥漫性大B细胞淋巴瘤患者在接受大剂量化疗和自体干细胞移植后接受利妥昔单抗单药治疗，实现持久完全缓解。
BMJ Case Rep. 2012 Jul 3;2012:bcr0220125856. doi: 10.1136/bcr.02.2012.5856.
3
Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma.绝对单核细胞/淋巴细胞计数预后评分独立于免疫组织化学确定的细胞起源，可预测弥漫性大 B 细胞淋巴瘤的生存。
Leuk Lymphoma. 2012 Nov;53(11):2159-65. doi: 10.3109/10428194.2012.690605. Epub 2012 May 21.
4
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.生发中心/活化 B 细胞亚类对复发/难治性弥漫性大 B 细胞淋巴瘤挽救治疗反应的预后影响：一项生物 CORAL 研究。
J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.
5
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.非生发中心 B 细胞样弥漫大 B 细胞淋巴瘤对来那度胺的反应高于生发中心 B 细胞样表型。
Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14.
6
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.2008 年世界卫生组织淋巴造血组织肿瘤分类及以后：不断发展的概念和实际应用。
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
7
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.一项评估口服 mTOR 抑制剂依维莫司治疗复发性侵袭性淋巴瘤的 II 期临床试验。
Leukemia. 2011 Feb;25(2):341-7. doi: 10.1038/leu.2010.226. Epub 2010 Dec 7.
8
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.利妥昔单抗、地塞米松、阿糖胞苷和奥沙利铂（R-DHAX）是一种在复发/难治性 B 细胞非霍奇金淋巴瘤中有效的、安全的挽救方案。
Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):262-9. doi: 10.3816/CLML.2010.n.055.
9
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.利妥昔单抗时代复发的大 B 细胞淋巴瘤的自体移植挽救治疗方案。
J Clin Oncol. 2010 Sep 20;28(27):4184-90. doi: 10.1200/JCO.2010.28.1618. Epub 2010 Jul 26.
10
Aggressive lymphomas.侵袭性淋巴瘤。
N Engl J Med. 2010 Apr 15;362(15):1417-29. doi: 10.1056/NEJMra0807082.
Zotero 插件